查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1857494

蛋白酪氨酸激酶抑制劑市場依適應症、標靶、代數、給藥途徑及通路分類－2025-2032年全球預測

Tyrosine Kinase Inhibitors Market by Indication, Target, Generation, Route Of Administration, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，蛋白酪氨酸激酶抑制劑市場規模將達到 1,117.5 億美元，複合年成長率為 7.32%。

關鍵市場統計數據
基準年 2024 634.6億美元
預計年份：2025年 682.1億美元
預測年份 2032 1117.5億美元
複合年成長率 (%) 7.32%

本文全面概述了蛋白酪氨酸激酶抑制劑如何從標靶治療概念轉變為現代腫瘤學的臨床和商業性重點。

蛋白酪氨酸激酶抑制劑透過將分子生物學知識轉化為標靶治療，再形成了腫瘤治療格局，並帶來了實際的臨床效益。在過去的二十年中，這些藥物已從實驗性療法轉變為多種腫瘤類型的主流療法，這得益於日益精準的生物標記識別和對抗藥性機制更深入的理解。新一代抑制劑的引入和更完善的患者選擇標準的製定，在逐步改善臨床療效的同時，也使競爭格局變得更加複雜，如今藥物的差異化取決於耐受性、抗藥性光譜和聯合用藥潛力。

當今的策略對話不僅強調分子療效，還強調整合伴隨診斷、適應性試驗設計以及支付方主導的證據要求的永續開發路徑。監管路徑與加速核准和條件性核准路徑同步發展，這要求研發人員在速度與驗證性證據的需求之間取得平衡。因此，相關人員必須協調臨床開發計劃、商業性准入策略和生產能力，以確保科學優勢轉化為病患可及性和商業性可行性。從概念驗證到永續的產品線，需要製定協調一致的跨職能計劃，並對不斷變化的臨床和監管數據做出靈活應對。

科學進步、適應性臨床設計、支付方期望和供應鏈韌性如何重塑蛋白酪氨酸激酶抑制劑生態系統

蛋白酪氨酸激酶抑制劑領域正經歷一系列變革性轉變，這些轉變正在重新定義產品的開發、定位和取得方式。科學進步加速了新型作用標靶的發現，並催生了旨在克服標靶抗藥性和中樞神經系統穿透性挑戰的新一代藥物。同時，臨床開發也變得更加迭代。籃子試驗和傘式試驗、適應性方案以及真實世界證據的整合正在縮短假設週期，並促成更動態的「批准/放棄」決策。

在商業性，差異化也正從單一藥物療效轉向更廣泛的價值提案，包括耐受性、治療順序策略以及與免疫療法和其他標靶藥物聯合使用的潛力。支付者和醫療系統越來越關注治療總成本和長期療效，促使生產商開發更完善的證據包和基於療效的合約。為因應地緣政治緊張局勢和監管審查，生產和供應鏈的韌性正成為策略重點，而數位化工具和分散式臨床試驗要素正在改善病患招募和留存。這些趨勢的融合需要一套新的策略，將嚴謹的科學性、商業性彈性和供應鏈前瞻性結合。

評估2025年美國關稅變化將如何重塑腫瘤藥物生產供應鏈的韌性、籌資策略和成本控制。

美國提案和已實施的關稅措施將持續到2025年，對支持腫瘤治療藥物生產的全球供應鏈產生了複雜的影響，尤其涉及蛋白酪氨酸激酶抑制劑、原料藥和關鍵組件的供應。跨境採購中間體和成品藥的製造商面臨潛在的成本壓力，這種壓力會波及採購、製造外包和分銷等各個環節。為此，許多公司正在評估其供應商的地理多元化，增加與本地或近岸製造企業的夥伴關係，並重新談判長期供應協議，以維持利潤率和供應的連續性。

關稅不僅影響直接成本考量，還會影響與製造地相關的庫存政策、前置作業時間和監管申報等策略決策。企業正在重新評估單一來源供應的可靠性，並盡可能加快雙重來源和策略儲備的投資。此外，關稅主導的價格壓力可能會加劇支付方的審查，並凸顯對更有力的藥物經濟學證據的需求，以證明下一代藥物高價的合理性。同時，貿易政策的不確定性迫使商業、監管和生產團隊更加緊密地合作，建立情境模型，降低中斷風險，並協調應急計劃，以確保在跨境成本結構變化的情況下，患者仍能獲得所需藥物。

詳細的細分分析，闡述了適應症、分子標靶、產品世代、給藥途徑和分銷管道如何影響產品策略。

市場細分洞察揭示了治療重點、機制靶向和發行策略的交匯點，從而影響臨床開發和商業化策略。基於適應症，本報告對乳癌、慢性骨髓性白血病、非小細胞肺癌和腎細胞癌市場進行了分析。慢性骨髓性白血病進一步細分為一線、第二線和三線線適應症。非小細胞肺癌也進一步細分為一線、第二線和三線適應症。這些基於適應症的區分至關重要，並會影響臨床試驗設計和標籤策略，因為固體癌和骨髓惡性腫瘤的預期臨床終點、競爭格局和標準治療方案存在顯著差異。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 針對T790M抗藥性EGFR突變的第三代TKI的研發
  • 增加對酪胺酸激酶抑制劑和免疫查核點抑制劑聯合治療的投資
  • 變構ABL激酶抑制劑的出現克服了BCR-ABL突變引起的抗藥性
  • 採用臨床基因組分析技術實現TKI治療方法的個人化
  • 生技創新者與製藥巨頭建立策略夥伴關係關係，加速TKI產品線開發
  • 一項真實世界證據研究評估了酪胺酸激酶抑制劑（TKI）在老年癌症患者群組中的安全性和有效性

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章蛋白酪氨酸激酶抑制劑市場依適應症分類

  • 乳癌
  • 慢性骨髓性白血病
    • 一線
    • 第二行
    • 三線
  • 非小細胞肺癌
    • 一線
    • 第二行
    • 三線
  • 腎臟細胞癌

第9章蛋白酪氨酸激酶抑制劑市場（以標靶分類）

  • 弧
  • Bcr-Abl
    • 第一代
    • 第二代
    • 第三代
  • EGFR
    • 第一代
    • 第二代
    • 第三代
  • Vegfr

第10章蛋白酪氨酸激酶抑制劑市場（按代分類）

  • 第一代
  • 第二代
  • 第三代

第11章蛋白酪氨酸激酶抑制劑市場依給藥途徑分類

  • 靜脈注射
  • 口服

第12章蛋白酪氨酸激酶抑制劑市場依通路分類

  • 醫院藥房
  • 零售藥房

第13章蛋白酪氨酸激酶抑制劑市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章蛋白酪氨酸激酶抑制劑市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國蛋白酪氨酸激酶抑制劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AstraZeneca PLC
    • Novartis AG
    • AbbVie Inc.
    • Eisai Co., Ltd.
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • Bristol-Myers Squibb Company
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Johnson & Johnson
Product Code: MRR-B168537796FC

The Tyrosine Kinase Inhibitors Market is projected to grow by USD 111.75 billion at a CAGR of 7.32% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 63.46 billion
Estimated Year [2025] USD 68.21 billion
Forecast Year [2032] USD 111.75 billion
CAGR (%) 7.32%

Comprehensive overview of how tyrosine kinase inhibitors transitioned from targeted concepts to integrated clinical and commercial priorities in modern oncology

Tyrosine kinase inhibitors have reshaped the therapeutic landscape for oncology by converting molecular insights into targeted therapies that deliver tangible clinical benefit. Over the past two decades, these agents have moved from experimental therapies to cornerstone treatments in multiple tumor types, driven by increasingly precise biomarker identification and enhanced understanding of resistance mechanisms. The introduction of successive generations of inhibitors and the refinement of patient selection criteria have progressively improved clinical outcomes while simultaneously complicating competitive dynamics as differentiation now rests on tolerability, resistance profiles, and combination potential.

Today's strategic conversations emphasize not only molecule-level efficacy but also durable development pathways that integrate companion diagnostics, adaptive trial designs, and payer-driven evidence requirements. Regulatory pathways continue to evolve alongside accelerated approvals and conditional pathways, prompting developers to balance speed with the need for confirmatory evidence. As a result, stakeholders must align clinical development plans, commercial access strategies, and manufacturing capabilities to ensure that scientific advantages convert into patient access and commercial viability. Transitioning from proof-of-concept to sustainable product franchises requires cohesive cross-functional planning and nimble responses to evolving clinical and regulatory data.

How scientific advances, adaptive clinical designs, payer expectations, and supply chain resilience are collectively redefining the tyrosine kinase inhibitor ecosystem

The landscape for tyrosine kinase inhibitors is undergoing a set of transformative shifts that are redefining how products are developed, positioned, and accessed. Scientific advances have accelerated the identification of novel actionable targets and led to the proliferation of next-generation agents designed to overcome on-target resistance and central nervous system penetration challenges. Concurrently, clinical development is becoming more iterative: basket and umbrella trials, adaptive protocols, and real-world evidence integration are shortening hypothesis cycles and enabling more dynamic go/no-go decisions.

Commercially, differentiation is migrating from single-agent efficacy to a broader value proposition that includes tolerability, sequencing strategies, and combination potential with immunotherapies and other targeted agents. Payers and health systems are increasingly focused on total cost of care and longitudinal outcomes, prompting manufacturers to develop more robust evidence packages and outcomes-based agreements. Manufacturing and supply chain resilience have emerged as strategic priorities in response to geopolitical tensions and regulatory scrutiny, while digital tools and decentralized trial elements are improving patient recruitment and retention. These converging trends require a new playbook that combines deep scientific rigor with commercial agility and supply chain foresight.

Assessment of how 2025 tariff changes in the United States are reshaping supply chain resilience, sourcing strategies, and cost management for oncology drug production

Proposed and implemented tariff measures in the United States for 2025 have introduced a complex set of implications for the global supply chains underpinning oncology drug production, with particular relevance for tyrosine kinase inhibitor supply, active pharmaceutical ingredients, and key componentry. Manufacturers that source intermediates or finished dosage forms across borders face potential cost pressures that can cascade through procurement, contract manufacturing, and distribution relationships. In response, many companies are evaluating the geographic diversification of suppliers, increasing use of local or near-shore manufacturing partnerships, and renegotiation of long-term supply agreements to preserve margin and continuity of supply.

Beyond immediate cost considerations, tariffs influence strategic decisions around inventory policies, lead times, and regulatory filings tied to manufacturing sites. Firms are reassessing the resilience of single-source dependencies and accelerating investments in dual-sourcing and strategic stockpiles where feasible. Moreover, tariff-driven price pressures can intensify payer scrutiny and amplify the need for stronger pharmacoeconomic evidence to justify premium pricing for next-generation agents. In parallel, trade policy uncertainty is prompting closer collaboration between commercial, regulatory, and manufacturing teams to model scenarios, mitigate disruption risk, and align contingency plans that maintain patient access despite shifting cross-border cost structures.

In-depth segmentation analysis explaining how indication, molecular target, generation, administration route, and distribution channels converge to shape product strategy

Segmentation insights illuminate where therapeutic focus, mechanistic targeting, and delivery strategies intersect to shape clinical development and commercialization approaches. Based on Indication, market is studied across Breast Cancer, Chronic Myeloid Leukemia, Non Small Cell Lung Cancer, and Renal Cell Carcinoma. The Chronic Myeloid Leukemia is further studied across First Line, Second Line, and Third Line. The Non Small Cell Lung Cancer is further studied across First Line, Second Line, and Third Line. These indication-focused distinctions are critical because clinical endpoint expectations, competitive backdrops, and standard-of-care sequences differ markedly between solid tumors and hematologic malignancies, influencing trial design and label strategy.

Based on Target, market is studied across Alk, Bcr-Abl, EGFR, and Vegfr. The Bcr-Abl is further studied across First Generation, Second Generation, and Third Generation. The EGFR is further studied across First Generation, Second Generation, and Third Generation. Target-specific segmentation highlights how molecular selectivity and resistance profiles drive differentiation and clinical positioning, while generational distinctions reflect evolutionary design efforts to improve potency and evade resistance. Based on Generation, market is studied across First Generation, Second Generation, and Third Generation; this lens helps clarify how incremental innovations shift tolerability and sequencing narratives. Based on Route Of Administration, market is studied across Intravenous and Oral, signaling divergent development, manufacturing, and adherence considerations that affect commercial uptake. Based on Distribution Channel, market is studied across Hospital Pharmacies and Retail Pharmacies, indicating where stakeholder engagement, channel economics, and patient access strategies will materially differ. Together, these segmentation dimensions provide an analytical scaffold to evaluate clinical opportunity, operational requirements, and commercial tactics across heterogeneous therapeutic contexts.

How regional regulatory diversity, payer dynamics, and local manufacturing priorities require differentiated global strategies for tyrosine kinase inhibitor development and access

Regional dynamics materially shape clinical development priorities, regulatory interactions, and commercialization pathways for tyrosine kinase inhibitors, and a region-sensitive perspective is essential to effective global strategy. In the Americas, regulatory agencies maintain accelerated approval mechanisms while payers increasingly demand robust health economic evidence and outcomes data to support reimbursement, driving early heath technology assessment engagement and expanded real-world evidence programs. In Europe, Middle East & Africa, regulatory heterogeneity and variable payer capabilities require tailored market access approaches, regional partnerships, and flexible pricing strategies to navigate reimbursement and tender processes across multiple jurisdictions. In Asia-Pacific, rapid enrollment capacities, rising domestic innovation ecosystems, and diverse regulatory frameworks create both swift commercial opportunities and complex local adaptation needs, particularly where manufacturing localization and technology transfer can support competitive positioning.

Across all regions, cross-border clinical collaboration and harmonized data generation approaches can streamline evidence development while region-specific commercialization playbooks must address distinct stakeholder landscapes, patient pathways, and distribution structures. Regulatory timelines, patient population characteristics, and healthcare financing models vary significantly, and therefore global programs must incorporate modular launch strategies that allow for concurrent but differentiated market entry plans. Adapting to regional nuances in clinical expectations and payer decision frameworks will be critical to maximizing the clinical and commercial impact of new tyrosine kinase inhibitor entrants.

Strategic competitive behaviors and partnership models that are driving product differentiation, pipeline prioritization, and commercialization effectiveness in targeted oncology therapies

Competitive behavior across pharmaceutical and biotech companies in the tyrosine kinase inhibitor space reflects an intense focus on sustaining innovation while optimizing commercial execution. Leading firms are increasingly prioritizing next-generation molecules designed to overcome resistance mutations and improve tolerability, while mid-sized and emerging companies often pursue niche indications or biomarker-defined populations to create defensible footholds. Partnerships between innovators and contract development organizations remain central to accelerating scale-up and maintaining flexibility in manufacturing, and licensing transactions continue to be a pragmatic route for regional commercialization and access.

Strategic pipelines emphasize complementary modalities such as antibody-drug conjugates, combination regimens with immunotherapies, and efforts to pair small-molecule inhibitors with precision diagnostic platforms. Business development activity focuses on securing late-stage assets or platform technologies that can be integrated into multi-line treatment sequences. At the same time, companies face increasing pressure to demonstrate value beyond clinical endpoints, necessitating investments in health economics teams, real-world evidence generation, and payer engagement capabilities. Operationally, organizations that invest early in scalable manufacturing, robust pharmacovigilance, and cross-functional launch readiness are better positioned to convert clinical differentiation into durable commercial performance.

Actionable strategic steps for industry leaders to strengthen portfolio focus, supply chain resilience, evidence generation, and commercialization readiness in oncology

To capture clinical and commercial upside in the evolving tyrosine kinase inhibitor environment, industry leaders should pursue a set of pragmatic, high-impact actions that align scientific differentiation with operational readiness. First, prioritize portfolio decisions that couple next-generation molecular design with clearly articulated clinical positioning and resistance management strategies to minimize late-stage repositioning risk. Second, fortify supply chain resilience by diversifying API and component sourcing, investing in dual-sourcing where feasible, and expanding near-shore manufacturing options to mitigate tariff and geopolitical exposure. Third, integrate value demonstration into development plans early by embedding health economic endpoints, real-world data collection, and patient-reported outcomes into registrational and post-marketing studies to support payer discussions and value-based contracting.

Additionally, embrace flexible trial methodologies such as adaptive designs and decentralized elements to accelerate enrollment and gather broader patient data while reducing cost and time to insight. Strengthen commercialization readiness through early stakeholder mapping, channel optimization for hospital and retail pharmacy pathways, and tailored regional launch plans that reflect local regulatory and payer requirements. Finally, pursue targeted collaborations-whether through licensing, co-development, or commercial partnerships-to extend geographic reach, accelerate scale-up, and combine complementary scientific assets. These actions collectively reduce execution risk and enable organizations to translate molecular advances into sustainable therapeutic impact.

Transparent and reproducible research methodology combining primary interviews, literature synthesis, patent and clinical pipeline analysis, and scenario-based triangulation of insights

The research methodology underpinning this analysis combines qualitative and quantitative approaches to synthesize clinical, regulatory, and commercial intelligence into an actionable view. Primary research included structured interviews with clinical investigators, regulatory specialists, payer advisors, and supply chain executives to capture first-hand perspectives on trial design preferences, reimbursement expectations, and operational constraints. Secondary research reviewed peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public company disclosures to triangulate development trends and historical regulatory precedents. Patent landscaping and clinical pipeline mapping informed assessments of mechanistic innovation and competitive density.

Data synthesis applied a triangulation approach to validate insights across independent sources, and scenario analysis was used to explore the operational implications of supply chain and policy shocks. Limitations are acknowledged, including the evolving nature of clinical data and policy changes that may shift the competitive landscape; accordingly, recommendations emphasize resilient, adaptable strategies rather than single-point predictions. The methodology prioritized reproducibility and transparency in assumptions, and where expert opinion supplemented public data, that synthesis was clearly flagged and cross-checked against available empirical evidence to ensure robustness.

Synthesis of strategic priorities showing how scientific innovation combined with operational resilience and evidence generation will determine long-term success in oncology

In conclusion, tyrosine kinase inhibitors remain a pivotal class of oncology therapeutics with continuous innovation driving both new clinical possibilities and heightened strategic complexity. Advances in molecular targeting, coupled with adaptive trial designs and an emphasis on real-world outcomes, are reshaping development paradigms and commercial expectations. External pressures such as trade policy shifts and supply chain vulnerabilities are compelling manufacturers to rethink sourcing strategies and to integrate resilience into their operational models. At the same time, regional regulatory divergence and evolving payer demands necessitate tailored access strategies that reconcile global evidence generation with local requirements.

Ultimately, organizations that align scientific differentiation with rigorous evidence generation, robust manufacturing planning, and region-specific commercialization readiness will be best positioned to convert therapeutic promise into clinical impact and sustainable business performance. Collaboration across clinical, regulatory, manufacturing, and commercial functions is essential, as is a willingness to adopt flexible development pathways and innovative contracting approaches that reflect the realities of modern oncology care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Development of third-generation TKIs targeting T790M-resistant EGFR mutations
  • 5.2. Increasing investment in combination therapies pairing TKIs with immune checkpoint inhibitors
  • 5.3. Emergence of allosteric ABL kinase inhibitors to overcome resistance from BCR-ABL mutations
  • 5.4. Adoption of genomic profiling in clinical practice to personalize TKI treatment regimens
  • 5.5. Strategic partnerships between biotech innovators and pharma giants to accelerate TKI pipeline development
  • 5.6. Real world evidence studies assessing safety and efficacy of TKIs in older cancer patient cohorts

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Tyrosine Kinase Inhibitors Market, by Indication

  • 8.1. Breast Cancer
  • 8.2. Chronic Myeloid Leukemia
    • 8.2.1. First Line
    • 8.2.2. Second Line
    • 8.2.3. Third Line
  • 8.3. Non Small Cell Lung Cancer
    • 8.3.1. First Line
    • 8.3.2. Second Line
    • 8.3.3. Third Line
  • 8.4. Renal Cell Carcinoma

9. Tyrosine Kinase Inhibitors Market, by Target

  • 9.1. Alk
  • 9.2. Bcr-Abl
    • 9.2.1. First Generation
    • 9.2.2. Second Generation
    • 9.2.3. Third Generation
  • 9.3. EGFR
    • 9.3.1. First Generation
    • 9.3.2. Second Generation
    • 9.3.3. Third Generation
  • 9.4. Vegfr

10. Tyrosine Kinase Inhibitors Market, by Generation

  • 10.1. First Generation
  • 10.2. Second Generation
  • 10.3. Third Generation

11. Tyrosine Kinase Inhibitors Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral

12. Tyrosine Kinase Inhibitors Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Retail Pharmacies

13. Tyrosine Kinase Inhibitors Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Tyrosine Kinase Inhibitors Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Tyrosine Kinase Inhibitors Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AstraZeneca PLC
    • 16.3.2. Novartis AG
    • 16.3.3. AbbVie Inc.
    • 16.3.4. Eisai Co., Ltd.
    • 16.3.5. Pfizer Inc.
    • 16.3.6. F. Hoffmann-La Roche Ltd
    • 16.3.7. Bristol-Myers Squibb Company
    • 16.3.8. Bayer AG
    • 16.3.9. Boehringer Ingelheim International GmbH
    • 16.3.10. Johnson & Johnson

LIST OF FIGURES

  • FIGURE 1. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. TYROSINE KINASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. TYROSINE KINASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TYROSINE KINASE INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST TY